"id","versionIdentifier","uuid:ID","rationale","instanceType"
"StudyVersion_1","2","cd855eec-c22f-4312-ad69-463ae5f33ede","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion"
